SWOT Analysis for Cns Pharmaceuticals Inc

Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Week
High Volume, High Gain
Top Gainers
Stock with Low PE (PE < = 10)
Volume Shockers
High Volume, High Gain
Biggest Price Gainers from Open

Stocks with Quarter Change % less than Industry
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Stocks Underperforming their Industry Price Change in the Quarter